BioRx, a Cincinnati-based national pharmacy specializing in bleeding disorders, announced the launch of a program designed for hemophilia patients with inhibitors. This new program, called IMPACT (Inhibitor Management Program), will stress education and enhanced clinical coordination to reach better outcomes for hemophilia patients suffering from this complication.
Educational programs for family members and school personnel, training aids and “treatment coaches” will be provided so that caregivers are more able to understand the complications of an inhibitor. In addition, increased clinical interventions by BioRx customer service and clinical staff plus enhanced coordination with physicians will be used to achieve better patient compliance to treatment. The ultimate goal of IMPACT is to improve clinical outcomes in patients with an inhibitor.
An inhibitor can develop when individuals with hemophilia produce antibodies to certain factor products, rendering treatment with these products ineffective. Approximately 15% to 30% of people with severe hemophilia A experience this complication. Inhibitor development in patients with severe hemophilia B is somewhat less common, occurring in about 1% to 4% of patients. The presence of an inhibitor complicates treatment and often leads to exorbitant health care costs.
“There are extraordinary financial, clinical and psychosocial challenges that are placed on these families when someone has been diagnosed with an inhibitor. We want to ensure that we are doing everything possible to give that family the best possible chance of dealing with it effectively,” said Mark Kestler, RPh, general manager of BioRx.
Source: BioRx news release dated April 12, 2006